Scrip World Pharmaceutical News
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 | |
| Type | News and analysis service |
|---|---|
| Format | Daily online |
| Owner(s) | Citeline |
| Publisher | Philip Jarvis |
| Founded | March 1972 |
| Headquarters | London, England |
| Website | www.scripnews.com |
Scrip Intelligence (Scrip) is an English language international pharmaceutical news, analysis and data service. First published as a weekly print newsletter in March 1972, Scrip included articles on side-effects, regulatory changes and mergers and acquisitions.
Overview
[edit]Scrip World Pharmaceutical News was initially published by advertising company J Walter Thomson but was bought by Dr Philip J Brown in 1976 for £2000, who founded PJB Publishing. Brown sold Scrip, associated titles, and his company to Informa for £150 million in 2003.[1][2][3]
Scrip has now developed into an online global pharma news and analysis service. It provides daily news and analysis on the biotechnology and pharmaceutical industry including areas such as policy & regulation, business news, research & development, generics, drug delivery, and clinical trials.
In 2022, Informa sold its Pharma Intelligence division, including Scrip, to Warburg Pincus.[4] The business was renamed Citeline. Later in 2022, Citeline was acquired by Norstella.
Editors
[edit]- Barbara Obstoj (1972–76)
- Philip Brown (1977–86)
- Moira Dower (1986–96)
- John Davis (1997–2007)
- Alex Shimmings (2007–2010)
- Mike Ward (2010–2012)
- Eleanor Malone (2014–present)
Subscribers
[edit]The Scrip readership has grown to over 100,000 worldwide,[5] half of which are in Europe. Scrip is read by managers and executives working across all disciplines in pharmaceutical and biotech companies worldwide.[6]
Editorial team
[edit]Scrip has a large independent editorial team of 21. The journalists are based throughout the world in Washington, D.C., Tokyo, India, and London to ensure a global emphasis to the latest news stories.
- "Science desk" - The R&D section tracks the fortune of marketed and developmental drugs, from clinical data to their passage through the regulatory process.[7][8]
- "Europe coverage" - Scrip's Europe based desk covers all the political and regulatory developments that affect the pharmaceutical industry in the 27 member states, other European countries and the Russian Federation.
- "US coverage" - Scrip's US team details the political developments from Washington affecting the global pharma industry, such as U.S. Food and Drug Administration safety and regulatory matters, as well as litigation, Generics and pharmacy.[9]
- "World coverage" - Scrip's locally based world coverage focuses on Japan and other Pacific Rim markets, Asia and Latin America.
- "Business news" - Scrip's global reporters bring information on financial and business affairs in the pharma and biotech sectors.[10]
- "Analyst team" - Scrip's analysts offer an insight into the industry's more significant developments.[11]
References
[edit]- ^ Wray, Richard (2003-12-03). "£2,000 niche buy nets £150m for science journalist". The Guardian. ISSN 0261-3077. Retrieved 2016-10-12.
- ^ "Three new Square fellows". Pharmaceutical Journal. Retrieved 2016-10-12.
- ^ "Informa buys PJB Publications for £120m – Press Gazette". www.pressgazette.co.uk. 3 December 2003. Retrieved 2016-10-12.
- ^ "Informa sells Pharma Intelligence to Warburg Pincus for £1.9B". www.spglobal.com. Retrieved 2023-11-03.
- ^ "Scrip's readership reaches over 100,000". scripnews.com. Retrieved 2008-08-04.
- ^ "Scrip's readers are global mid-senior level management". scripnews.com. Retrieved 2008-08-04.
- ^ "Research and development news". scripnews.com. Retrieved 2008-08-04.
- ^ "Clinical trials news". scripnews.com. Retrieved 2008-08-04.
- ^ "Policy and regulation news". scripnews.com. Retrieved 2008-08-04.
- ^ "Financial news". scripnews.com. Retrieved 2008-08-04.
- ^ "Scrip's analysis team". scripnews.com. Retrieved 2008-08-04.
